GeneOne Life Science Inc and Walter Reed Army Institute of Research (WRAIR) have signed a cooperative research and development agreement to advance GLS-5300, GeneOne’s DNA vaccine for Middle East respiratory syndrome (MERS). GeneOne is co-developing GLS-5300 with its affiliate Inovio Pharmaceuticals.
As part of this agreement, GeneOne and WRAIR will test the GLS-5300 vaccine in a first-in-human phase I clinical study to be executed at the WRAIR’s Clinical Trials Center. WRAIR will be responsible for all relevant MERS vaccine clinical trial procedures and costs at the Walter Reed Army Institute of Research.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management